{"relation": [["", "Pio15/Pio30", "Pio30/Pio30", "Pio45/Pio45", "Lina5/Lina5", "Lina5Pio15/Lina5Pio30", "Lina5Pio30/Lina5Pio30", "Lina5Pio45/Lina5Pio45", "Total"], ["Description", "Participants treated with pioglitazone 15mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.", "Participants treated with pioglitazone 30mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.", "Participants treated with pioglitazone 30 mg for 6 weeks and then were titrated up to pioglitazone 45mg for 24 weeks followed by pioglitazone 45mg for up to 54 weeks.", "Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.", "Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for 30 weeks followed by a blinded trial period on linagliptin 5mg + pioglitazone 30mg FDC", "Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.", "Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 6 weeks and linagliptin 5mg + pioglitazone 45mg FDC for 24 weeks followed by linagliptin 5mg + pioglitazone 45mg FDC for up to 54 weeks.", "Total of all reporting groups"]], "pageTitle": "30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT01183013?term=%22Type+2+Diabetes%22&lup_s=07%2F02%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 7, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981856.5/warc/CC-MAIN-20150728002301-00199-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 856490379, "recordOffset": 856478925, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details After Amendment #5, patients were considered COMPLETED at the end of Part A (30 weeks) or after their next Part B visit (up to 54 weeks) if already in Part B. Before Amendment #5, all patients were considered COMPLETED at the end of Part A + Part B (84 weeks). Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Pioglitazone 15 mg Drug: Pioglitazone 45 mg Drug: Pioglitazone 30 mg Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC Drug: Linagliptin 5mg Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC", "textAfterTable": "\u00a0 \u00a0 Pio15/Pio30 \u00a0 \u00a0 Pio30/Pio30 \u00a0 \u00a0 Pio45/Pio45 \u00a0 \u00a0 Lina5/Lina5 \u00a0 \u00a0 Lina5Pio15/Lina5Pio30 \u00a0 \u00a0 Lina5Pio30/Lina5Pio30 \u00a0 \u00a0 Lina5Pio45/Lina5Pio45 \u00a0 STARTED \u00a0 \u00a0 131 \u00a0 \u00a0 140 \u00a0 \u00a0 138 \u00a0 \u00a0 135 \u00a0 \u00a0 126 \u00a0 \u00a0 133 \u00a0 \u00a0 133 \u00a0 COMPLETED \u00a0 \u00a0 86 [1] \u00a0 101 [1] \u00a0 97 [1] \u00a0 105 [1] \u00a0 90 [1] \u00a0 88 [1] \u00a0 96 [1] NOT COMPLETED \u00a0 \u00a0 45 \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}